RxSight, Inc. will announce Q3 2025 financial results on November 5, 2025, followed by a conference call.
Quiver AI Summary
RxSight, Inc., a company focused on enhancing vision quality following cataract surgery, will release its third-quarter financial results for 2025 after the market closes on November 5, 2025. Management will host a conference call at 1:30 p.m. PT to discuss these results, which can be accessed by calling specific numbers or via a live broadcast on the company's investor relations website. The RxSight® Light Adjustable Lens system is highlighted as the only adjustable intraocular lens technology available that allows customized vision for patients after surgery. Further details about the company are available on its website.
Potential Positives
- RxSight is set to report its financial results for the third quarter of 2025, indicating transparency and a commitment to shareholder communication.
- The company will host a conference call to discuss the financial results, providing an opportunity for investors and analysts to engage with management directly.
- RxSight's proprietary Light Adjustable Lens system represents a unique advancement in cataract surgery, showcasing the company’s innovation and potential competitive advantage in the ophthalmic medical device market.
Potential Negatives
- Financial results reporting may indicate upcoming challenges if results are less favorable than expectations.
- The need for a conference call to discuss financial results could suggest previous volatility or concerns that need clarification.
- No specific projections or forecasts were included in the release, which may indicate a lack of confidence in future performance.
FAQ
When will RxSight report its Q3 2025 financial results?
RxSight will report its third quarter financial results on November 5, 2025, after market close.
What time is the conference call for RxSight's financial results?
The conference call will start at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
How can I participate in RxSight's conference call?
To participate, dial (800) 715-9871 or (646) 307-1963, and use the conference code: 6619966.
Will the conference call be available for later listening?
Yes, an archived recording of the call will be available shortly after it concludes on the investor relations website.
What is the RxSight Light Adjustable Lens system?
The RxSight Light Adjustable Lens system allows customization of vision after cataract surgery, offering high-quality results for patients.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RXST Hedge Fund Activity
We have seen 109 institutional investors add shares of $RXST stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ removed 2,041,084 shares (-93.5%) from their portfolio in Q2 2025, for an estimated $26,534,092
- D. E. SHAW & CO., INC. added 1,299,330 shares (+5906.0%) to their portfolio in Q2 2025, for an estimated $16,891,290
- DEERFIELD MANAGEMENT COMPANY, L.P. added 888,950 shares (+inf%) to their portfolio in Q2 2025, for an estimated $11,556,350
- FMR LLC removed 876,617 shares (-84.8%) from their portfolio in Q2 2025, for an estimated $11,396,021
- CITADEL ADVISORS LLC added 797,642 shares (+346.5%) to their portfolio in Q2 2025, for an estimated $10,369,346
- WELLINGTON MANAGEMENT GROUP LLP added 727,952 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,463,376
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 719,486 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $9,353,318
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RXST Analyst Ratings
Wall Street analysts have issued reports on $RXST in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 07/09/2025
- B of A Securities issued a "Underperform" rating on 07/09/2025
To track analyst ratings and price targets for $RXST, check out Quiver Quantitative's $RXST forecast page.
$RXST Price Targets
Multiple analysts have issued price targets for $RXST recently. We have seen 8 analysts offer price targets for $RXST in the last 6 months, with a median target of $9.0.
Here are some recent targets:
- Tom Stephan from Stifel set a target price of $8.0 on 08/08/2025
- David Saxon from Needham set a target price of $11.0 on 08/08/2025
- Danielle Antalffy from UBS set a target price of $8.0 on 08/08/2025
- Patrick Wood from Morgan Stanley set a target price of $9.0 on 07/15/2025
- Young Li from Jefferies set a target price of $9.0 on 07/10/2025
- Adam Maeder from Piper Sandler set a target price of $10.0 on 07/09/2025
- Larry Biegelsen from Wells Fargo set a target price of $9.0 on 07/09/2025
Full Release
ALISO VIEJO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the third quarter of 2025 after the market close on Wednesday, November 5, 2025. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 6619966. The call will also be broadcast live in listen-only mode via a link on the company’s investor relations website at https://investors.rxsight.com/ . An archived recording of the call will be available through the same link shortly after its completion.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com .
Company Contact:
Shelley B. Thunen
Chief Financial Officer
[email protected]
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
[email protected]
